WO2003014329A3 - Modulation of angiogenesis by a-beta peptides - Google Patents
Modulation of angiogenesis by a-beta peptides Download PDFInfo
- Publication number
- WO2003014329A3 WO2003014329A3 PCT/US2002/027040 US0227040W WO03014329A3 WO 2003014329 A3 WO2003014329 A3 WO 2003014329A3 US 0227040 W US0227040 W US 0227040W WO 03014329 A3 WO03014329 A3 WO 03014329A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- diseases
- kits
- angiogenic
- angiogenesis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002467922A CA2467922A1 (en) | 2001-08-10 | 2002-08-12 | Modulation of angiogenesis by a-beta peptides |
EP02759452A EP1424892A4 (en) | 2001-08-10 | 2002-08-12 | Modulation of angiogenesis by a-beta peptides |
AU2002324787A AU2002324787A1 (en) | 2001-08-10 | 2002-08-12 | Modulation of angiogenesis by a-beta peptides |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31165601P | 2001-08-10 | 2001-08-10 | |
US60/311,656 | 2001-08-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003014329A2 WO2003014329A2 (en) | 2003-02-20 |
WO2003014329A3 true WO2003014329A3 (en) | 2004-02-12 |
Family
ID=23207880
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/027040 WO2003014329A2 (en) | 2001-08-10 | 2002-08-12 | Modulation of angiogenesis by a-beta peptides |
Country Status (5)
Country | Link |
---|---|
US (1) | US7589168B2 (en) |
EP (1) | EP1424892A4 (en) |
AU (1) | AU2002324787A1 (en) |
CA (1) | CA2467922A1 (en) |
WO (1) | WO2003014329A2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8691224B2 (en) | 2005-11-30 | 2014-04-08 | Abbvie Inc. | Anti-Aβ globulomer 5F7 antibodies |
US8877190B2 (en) | 2006-11-30 | 2014-11-04 | Abbvie Inc. | Aβ conformer selective anti-Aβ globulomer monoclonal antibodies |
US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
US8987419B2 (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
US9176150B2 (en) | 2003-01-31 | 2015-11-03 | AbbVie Deutschland GmbH & Co. KG | Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3910569B2 (en) * | 2003-08-19 | 2007-04-25 | 独立行政法人科学技術振興機構 | Reagent for amplifying amyloid fibrillation of amyloid β protein |
EP1951750A4 (en) * | 2005-11-10 | 2009-12-09 | Roskamp Res Llc | Modulation of angiogenesis by a-beta peptide fragments |
US8263558B2 (en) | 2005-11-30 | 2012-09-11 | Abbott Laboratories | Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins |
CN101506236B (en) | 2005-11-30 | 2012-12-12 | 雅培制药有限公司 | Monoclonal antibodies against amyloid beta protein and uses thereof |
US8227413B2 (en) | 2006-10-19 | 2012-07-24 | Ramot At Tel-Aviv University Ltd. | Compositions and methods for inducing angiogenesis |
JP5817060B2 (en) | 2008-04-14 | 2015-11-18 | アルツィノヴァ エービー | Purified peptides, soluble oligomers containing purified peptides, methods for identifying compounds suitable for disease treatment using purified peptides or soluble oligomers, purified using purified peptides or soluble oligomers Methods for selecting binding proteins that react with peptides or soluble oligomers, use of purified peptides or soluble oligomers in the production of pharmaceutical compositions, pharmaceutical preparations containing purified peptides or soluble oligomers, purified peptides or soluble oligomers A vaccine comprising a purified peptide or a soluble oligomer, a method for preventing or treating a mammal other than a human, a non-human transgenic gene wherein APP expresses a nucleotide encoding APP containing two cysteines Animals, non-human transgenic animals expressing nucleotides encoding purified peptides, polypeptides where APP is an APP containing two cysteines, purified peptides or nucleotides encoding polypeptides, purified peptides Or an expression system comprising a nucleotide encoding a polypeptide |
JP6147665B2 (en) | 2010-08-14 | 2017-06-14 | アッヴィ・インコーポレイテッド | Amyloid beta-binding protein |
US9890201B2 (en) | 2013-08-02 | 2018-02-13 | International Park Of Creativity | Biological devices and methods of use thereof for the study and control of alzheimer's disease |
GB201319656D0 (en) * | 2013-11-07 | 2013-12-25 | Univ Leuven Kath | A yeast model for synergistic toxicity |
US20230025293A1 (en) * | 2021-07-16 | 2023-01-26 | Far Eastern Memorial Hospital | Methods and kits for diagnosing mild cognitive impairment |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994010569A1 (en) * | 1992-10-26 | 1994-05-11 | Schenk Dale B | METHODS AND COMPOSITIONS FOR THE DETECTION OF SOLUBLE β-AMYLOID PEPTIDE |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5981471A (en) * | 1997-02-06 | 1999-11-09 | Entremed, Inc. | Compositions and methods for inhibiting cellular proliferation |
-
2002
- 2002-08-12 CA CA002467922A patent/CA2467922A1/en not_active Abandoned
- 2002-08-12 EP EP02759452A patent/EP1424892A4/en not_active Withdrawn
- 2002-08-12 WO PCT/US2002/027040 patent/WO2003014329A2/en not_active Application Discontinuation
- 2002-08-12 AU AU2002324787A patent/AU2002324787A1/en not_active Abandoned
- 2002-08-12 US US10/217,584 patent/US7589168B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994010569A1 (en) * | 1992-10-26 | 1994-05-11 | Schenk Dale B | METHODS AND COMPOSITIONS FOR THE DETECTION OF SOLUBLE β-AMYLOID PEPTIDE |
Non-Patent Citations (3)
Title |
---|
PARIS ET AL.: "Soluble beta-amyloid peptides mediate vasoactivity via activation of a pro-inflammatory pathway", NEUROBIOLOGY OF AGING, vol. 21, 2000, pages 183 - 197, XP001151845 * |
See also references of EP1424892A4 * |
TARKOWSKI ET AL.: "Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia", NEUROBIOLOGY OF AGING, vol. 23, 2002, pages 237 - 243, XP002969167 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9176150B2 (en) | 2003-01-31 | 2015-11-03 | AbbVie Deutschland GmbH & Co. KG | Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof |
US8691224B2 (en) | 2005-11-30 | 2014-04-08 | Abbvie Inc. | Anti-Aβ globulomer 5F7 antibodies |
US9540432B2 (en) | 2005-11-30 | 2017-01-10 | AbbVie Deutschland GmbH & Co. KG | Anti-Aβ globulomer 7C6 antibodies |
US8877190B2 (en) | 2006-11-30 | 2014-11-04 | Abbvie Inc. | Aβ conformer selective anti-Aβ globulomer monoclonal antibodies |
US9359430B2 (en) | 2006-11-30 | 2016-06-07 | Abbvie Inc. | Abeta conformer selective anti-Abeta globulomer monoclonal antibodies |
US9394360B2 (en) | 2006-11-30 | 2016-07-19 | Abbvie Inc. | Aβ conformer selective anti-Aβ globulomer monoclonal antibodies |
US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
US8987419B2 (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
Also Published As
Publication number | Publication date |
---|---|
US7589168B2 (en) | 2009-09-15 |
EP1424892A4 (en) | 2006-08-23 |
US20030077261A1 (en) | 2003-04-24 |
WO2003014329A2 (en) | 2003-02-20 |
CA2467922A1 (en) | 2003-02-20 |
EP1424892A2 (en) | 2004-06-09 |
AU2002324787A1 (en) | 2003-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003014329A3 (en) | Modulation of angiogenesis by a-beta peptides | |
WO2002046222A3 (en) | Compositions and methods for diagnosing alzheimer's disease | |
HK1160392A1 (en) | Determination of the prognosis of a patient undergoing treatment for alzheimer's disease | |
EP2006298A3 (en) | Juvenile hemochromatosis gene (HFE2A), expression products and uses thereof | |
ATE468137T1 (en) | INHIBITORS OF HMGB1 FOR THE TREATMENT OF TISSUE DISEASES | |
MXPA02011656A (en) | Nrg 2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods. | |
AU1922101A (en) | Human fgf-21 gene and gene expression products | |
EP1140170A4 (en) | Novel agents and methods for treatment and diagnosis of ocular disorders | |
WO2001009118A3 (en) | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement | |
SG49841A1 (en) | Keratinocyte growth factor (kfg) for its use in method of therapeutic treatment for the human or animal body | |
WO2003040183A3 (en) | Compounds for the diagnosis/prevention/treatment of alzheimer's disease | |
TR199903154T2 (en) | Compositions and methods for the treatment and diagnosis of breast cancer | |
WO2002050277A3 (en) | Protein and nucleic acids encoding same | |
EP1286590A4 (en) | Peptide analogs and mimetics suitable for in vivo use in the treatment of diseases associated with abnormal protein folding into amyloid, amyloid-like deposits or beta-sheet rich pathological precursor thereof | |
EP1978362A3 (en) | Cross beta structure comprising amyloid binding proteins and methods for detection of the cross beta structure, for modulating cross beta structures fibril formation and for modulating cross beta structure-mediated toxicity | |
Abraham et al. | Osteoporosis and schizophrenia: can we limit known risk factors? | |
DE59310320D1 (en) | New means of diagnosing vascular diseases | |
DE69835680D1 (en) | THERAPEUTIC USE OF SMR1 PROTEIN AND ITS ACTIVE DERIVATIVES | |
SG121733A1 (en) | Nucleic acid molecules polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease | |
WO2004055201A3 (en) | Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease | |
ATE374618T1 (en) | USE OF RECOMBINANT HUMAN UTEROGLOBIN FOR THE TREATMENT OF FIBROTIC DISEASES | |
BG106051A (en) | MUTATIONS OF THE ENDOTHELIUM NITROGEN OXIDE SYNTHETASIS, eNOS AND THIEIR APPLICATION FOR GENE THERAPY AND THRAPEUTIC SCREENING | |
EA200200533A1 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE IN VIVO DELIVERY OF GENES | |
WO2001062799A3 (en) | Method for inhibiting angiogenesis using molecules that enhance plasmin activity | |
WO1999051186A3 (en) | Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002759452 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2467922 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 2002759452 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |